This site is intended for Healthcare Professionals only.

NICE recommends Midostaurin for rare blood disorder

Date:

Share post:

Midostaurin can be used to treat advanced systemic mastocytosis in adults, recommended NICE in the draft guidance published on Thursday (August 19).

Following the new draft guidance, around 170 patients will now be eligible for treatment with midostaurin, the first targeted therapy for advanced systemic mastocytosis to be available on the NHS.

The treatment is taken orally twice a day and works by blocking multiple enzymes involved in the condition.

Clinical trial evidence suggests that midostaurin improves the overall survival of people with advanced systemic mastocytosis compared to several comparator treatments. There is also a substantial improvement in the quality of life for patients using midostaurin, however evidence around its effectiveness is uncertain.

Therefore, midostaurin is considered a cost-effective use of NHS resources and is recommended for routine use on the NHS.

Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, said: “We are pleased to be able to recommend midostaurin as a treatment option for people with advanced systemic mastocytosis, despite the limitations in the clinical and comparative effectiveness evidence.

“The symptoms experienced by patients with this rare disease can be devastating and limiting. By recognising that patients with advanced systemic mastocytosis have a limited life expectancy without midostaurin, and by working closely with the company, we can support access to this innovative treatment.”

Blake Dark, interim Chief Commercial Officer at NHS England said: “As the first targeted therapy for this form of blood disorder available on the NHS, patients with advanced systemic mastocytosis will now have their chances of survival improved while experiencing a better quality of life.

“This deal is another example of how the NHS is securing access to treatments for rare conditions, that are value for money for taxpayers.”

Mastocytosis is a rare condition caused by an excess number of specific blood cells called mast cells, which play a key role in the immune system by triggering inflammation in the body. Advanced systemic mastocytosis is a severe form of the disease where mast cells gather in body tissues, such as the skin, internal organs and bones.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

How pharmacists can help children and young people with asthma: 2024 AskAboutAsthma campaign highlights

The 2024 #AskAboutAsthma campaign calls on pharmacists to take an active role in improving asthma management and outcomes...

Huxley Europe relaunches HuxQ10 Capsules with triple certification

The relaunch underscores Huxley Europe's commitment to health and welfare, offering specially developed formulas for users with dietary...

Alastair Buxton outlines vision for Community Pharmacy at Westminster Health Forum

Alastair Buxton, Director of NHS Services at CPE, outlines critical issues and solutions at the Westminster Health Forum,...

Food prices remain UK consumers’ top concern, FSA report finds

Consumers worried about food affordability were more likely to take food safety risks to save money The Food...